PharmaVoice, February 2012 - In recent years, the research and development landscape in the pharmaceutical industry has radically changed. The search for the next big blockbuster has been replaced by the search for medicines targeted toward specific patient subpopulations or toward diseases with high unmet medical need to make up the gaping hole left by blockbuster patent expiries.

To supplement their portfolios, big pharmaceutical companies are increasingly looking toward partnerships, not only to lessen the costs of developing a compound from scratch but also to take advantage of the wealth of innovation and cutting-edge science found in academia, start-ups, and small biotech companies.